Sector: Health Care
Director information for PALVELLA THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Christopher Kiritsy | Director | 61 | ["Founder and managing member of Precision Kapital, LLC","Co-founder and served as President and CEO of Arisaph Pharmaceuticals, Inc.","Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc.","Oversaw development of cardiometabolic products","Raised approximately $500 million in public equity capital","Experience in building publicly traded companies"] | ["Audit","Nominating and Corporate Governance"] | 2026 |
| ELAINE J. HERON, PH.D. | Director | 78 | ["extensive experience in life science sales and marketing","finance and accounting","corporate governance matters","research and development"] | ["Audit","Nominating and Corporate Governance (Chair)"] | 2026 |
| GEORGE M. JENKINS | Director; Board member | 74 | ["served as a member of Legacy Palvella’s board of directors from March 2017 to December 2024","general partner of Apax Partners from 1987 until 2005","serves as a board member of several private companies, including Conventus Orthopaedics, Inc.","has served on the board of various public and private companies, including SkinMedica, Colorescience, Sunglass Hut, and Spyder Active Sports","holds an M.B.A. from Pace University","holds a B.A. in Economics from Lafayette College","Trustee Emeritus at Lafayette College","extensive experience in healthcare investment management","executive leadership and directorship experience"] | ["Audit (Chair)","Compensation"] | 2026 |
| John Doux, M.D. | Analyst, Palo Alto Investors LP; Director | 57 | ["Board-certified dermatologist","Fellow of the American Academy of Dermatology","Analyst at Palo Alto Investors LP","Co-founded the Dermatology Summit and the Dermatology Innovation Forum","Board trustee for the Pachyonychia Congenita Project","Director on the board of Kamari Pharma","Served on the board of directors of Legacy Palvella","Experience with multiple biotechnology companies","Clinical practice in medical and surgical dermatology","B.S. and M.D. from Stanford University","Howard Hughes Medical Institute Fellow","MBA from Wharton School of Business"] | [] | 2026 |
| Tadd S. Wessel | Director | 50 | ["Founder and Managing Partner of Petrichor","Founder and Managing Partner of Scion Life Sciences","More than 25 years of experience in the life sciences sectors","Former Partner at OrbiMed Advisors LLC","Former Vice President at Fortress Investment Group","Experience in life sciences investment banking at Citigroup and Robertson Stephens","Served on more than 30 boards including Aurion Biotech and ITM Isotope Technologies Munich SE","Advisory Board member of the AIM at Melanoma Foundation","Board member of the International Centers for Precision Oncology","AB in biology from Princeton University"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
| TODD C. DAVIS | Chief Executive Officer of Ligand Pharmaceuticals, Incorporated | 65 | ["Extensive experience in the healthcare industry","Experience in healthcare investment management","Experience as a director of a publicly held biopharmaceutical company"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
| Wesley H. Kaupinen | President, Chief Executive Officer and Director | 48 | ["Knowledge of Legacy Palvella’s business","Extensive leadership experience","Successful record of commercial operations and product pipeline development"] | [] | 2026 |
